Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial

Assessment of vascular response to BiOSS LIM C® stents vs Orsiro® stents in the porcine coronary artery model

“…The first BiOSS ® stent was a bare metal one, but shortly after a paclitaxel‐eluting version was introduced into the market—the BiOSS Expert ® stent (CE Mark 2011). After acceptable results of the BiOSS Expert ® stent in two registries and in the randomized clinical trial POLBOS I (Polish Bifurcation Optimization Strategy), an option for improvement was to change paclitaxel into the olimus drug. The sirolimus was chosen, and the BiOSS LIM ® stent was developed (CE Mark 2012).…”

“…Nevertheless, the optimal approach for true coronary bifurcations is still a subject of discussion, especially when the side branch is large, narrowed by a long plaque or not simply accessible . The role of dedicated devices in this setting remains unclear compared to the provisional approach as shown in the Tryton IDE study or POLBOS I and II trials …”

“…2 The role of dedicated devices in this setting remains unclear compared to the provisional approach as shown in the Tryton IDE study or POLBOS I and II trials. [3][4][5] As a mean to further improve performance of one of the dedicated bifurcation stents, Balton Company developed a new coronary version of BiOSS ® stent-BiOSS LIM C ® cobalt-chromium sirolimus-eluting stent with the biodegradable polymer. The aim of this study was to evaluate 28-day safety profile and biocompatibility of BiOSS LIM C ® stent in the nondiseased porcine coronary artery model.…”

The Need For Dedicated Bifurcation Stents: A Critical Analysis

“…In the POLBOS (Polish Bifurcation Optimal Stenting) I randomised study, the BiOSS Expert stent was compared with regular DES. 17 A total of 243 patients were enrolled and randomised (1:1) to receive either treatment. Additional SB stenting was required in 10 % of cases in both groups.…”

Complex Percutaneous Interventions: What Is the Role for Specialized Bifurcation Stents?

“…14 In this issue of the Canadian Journal of Cardiology, the BiOSS Expert stent (Balton, Warsaw, Poland), a DES bifurcation stent that elutes paclitaxel, was compared with a conventional DES in the first randomized trial of a dedicated DES bifurcation stent and contemporary bifurcation strategy (DES with provisional stenting of the SB). 15 The BiOSS Expert stent belongs to the category of dedicated bifurcation stents that improve access for SB intervention without actual stenting of the SB. The access is achieved by a design that consists of only 2 struts in the pericarinal region.…”